Abstract 189P
Background
Malignant tumors are sophisticated, organized ecosystems in addition to collections of cancer cells. It has long been established that the formation, recurrence, and metastasis of cancers are all tightly correlated with their immune components. However, the impact of the tumor microenvironment in soft tissue sarcoma (STS) remains mainly unclear. Studying how the immunological microenvironment affects the clinical presentation and prognosis of soft tissue sarcomas is the objective.
Methods
Retrospective research was conducted on 168 soft tissue sarcoma patients who received care at the Republican specialized Scientific and practical Medical Center of Oncology and Radiology of Uzbekistan. Through immunohistochemistry analyses of CD3, CD4, CD8, CD20, and CD68, lymphocyte subpopulations that infiltrate tumours and their subpopulations were investigated.
Results
In the immunological microenvironment, CD 68+ macrophages and CD 3+ T cells were the most prevalent cell types. There was a substantial positive correlation between CD 68 expression and the probability of local recurrence (p = 0.014) in a multivariate analysis employing the Fine & Gray risk regression model with death as a competing event, independent of age, resection margins, and the presence of B cells. Furthermore, B cell abundance was significantly lower (p = 0.013) and macrophage abundance was much higher in patients older than middle age. Regarding histological subtypes, undifferentiated pleomorphic sarcoma and myxofibrosarcoma were more frequently found to have these cells, which had a high total number of tumor-infiltrating lymphocytes in general and macrophages in particular.
Conclusions
The significant number of CD 68 macrophages in soft tissue sarcomas and their detrimental effect on the prognosis for local recurrence are both confirmed by this investigation.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors
Presenter: Jan Podhorec
Session: Poster Display
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display